A recent article discusses emerging research on a newer blood-based test designed to help physicians better understand disease activity in multiple sclerosis.
The study referenced in this coverage included Dr. Taylor (Gonyou) Hess, a fellowship-trained multiple sclerosis neurologist at MIND, who served as an investigator on a study evaluating how biomarker data can support more informed treatment decisions over time. This type of testing examines multiple biological signals in the blood linked to MS activity — including immune system behavior, nerve injury, inflammation, and myelin damage or repair — helping clinicians build a more complete picture of what may be happening between visits and imaging studies.
When used alongside clinical exams and imaging, this information may provide additional insight into relapse risk and treatment response over time.
At MIND, blood-based biomarker testing may be used in select cases as part of MS care when clinically appropriate, based on physician judgment and individual patient needs.
Physician-led research like this underscores MIND’s ongoing commitment to advancing MS care through evidence-based medicine and clinical innovation.
Read the article: https://www.rarediseaseadvisor.com/patient-columns/its-now-easier-to-get-the-new-ms-test/































